ToxStrategies, a Texas-based, multidisciplinary scientific consulting company, announced on Tuesday that it has acquired Clintrex Research Corporation, a Florida-based company that provides scientific, clinical trial, operational and regulatory assistance to pharmaceutical and biotech companies engaged in the development of new therapies for central nervous system disorders.
The acquired company was founded by Dr C. Warren Olanow, Dr Karl Kieburtz, and Cornelia Kamp. Terms of the transaction were not disclosed.
ToxStrategies partnered with Renovus Capital Partners in November 2022, with the aim of expanding its present client base and developing new end markets. The acquisition of Clintrex by ToxStrategies brings together two best-in-class firms within the life sciences industry, with a unified focus on providing integrated teams to solve the multifaceted problems and challenges faced by our clients, particularly in the drug development space. Drs Olanow and Kieburtz will continue to lead Clintrex as a Division of ToxStrategies.
President of ToxStrategies, Dr Laurie Couture Haws, PhD, DABT, ATS, said: "We are proud to welcome Clintrex physicians, scientists and regulatory specialists to our growing team of toxicologists, epidemiologists, biostatisticians, engineers, and health economics and outcome research (HEOR) analysts working to develop and assist with FDA approval of life-changing therapies, as well as providing expertise in the optimisation of the biopharmaceutical cold chain for novel, fragile, and temperature controlled therapies."
Vesper Bio announces positive Phase I results for FTD treatment
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Argent BioPharma partners with SINTEF to advance chronic wound management
NRx Pharmaceuticals and HOPE Therapeutics align with FDA on Pediatric Study Plan for NRX-100
TPG invests in K2 Medical Research to expand clinical trial site platform
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Lipocine doses first cohort in LPCN 1154 study
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours